eClinicalWorks and healow Genie to Transform Patient Care at America's Family Doctors
WESTBOROUGH, Mass.--(BUSINESS WIRE)-- eClinicalWorks®, the largest ambulatory cloud EHR, proudly announces that America's Family Doctors has selected healow® Genie, an AI-driven contact center solution. This collaboration marks a significant milestone in America's Family Doctors' mission to enhance patient care capabilities and revolutionize healthcare experiences for its patients. By integrating healow Genie's advanced technologies, the practice aims to streamline patient communication, optimize appointment scheduling, and provide unparalleled access to essential health information, reaffirming its position as a pioneer in leveraging cutting-edge solutions to improve healthcare standards.
"We selected healow Genie to elevate our patient care capabilities and provide exceptional healthcare experiences to our patients," said Dr. Steve Samudrala, medical director and founder of America's Family Doctors. "As a PCMH-certified practice, we are dedicated to leveraging advanced technologies like healow Genie to enhance patient engagement, simplify appointment scheduling, and ensure continuous access to vital health information. Alongside healow Genie, innovative healow products such as healow Chatbot and healow Open Access further empower us to offer seamless patient communication and convenient appointment scheduling options."
America's Family Doctors has been at the forefront of adopting innovative healthcare technologies to deliver high-quality medical services to its expanding patient base. Renowned for its comprehensive primary care offerings, America's Family Doctors utilizes cutting-edge technologies, such as the healow product suite, to enhance patient care quality, operational efficiency, and adaptability for its community.
'With the integration of healow Genie, we are incredibly excited to transform patient communication and empower healthcare practices like America's Family Doctors," said Girish Navani, CEO and co-founder of eClinicalWorks. 'With AI-powered technology like healow Genie, we want to elevate the patient journey, drive operational effectiveness, and support the practice's growth. By enhancing healthcare information accessibility, simplifying appointment scheduling, and improving the overall patient experience, eClinicalWorks and healow Genie are ready to make a significant impact at America's Family Doctors."
healow Genie is a cutting-edge solution designed to revolutionize patient communication, improve access to healthcare information, and streamline appointment coordination. The AI-powered contact center solution features patient self-service options, intelligent assistance functionalities, automated after-hours services, and engaging marketing campaigns. healow Genie is poised to significantly elevate the healthcare experience for America's Family Doctors patients.
Watch this video to learn why America's Family Doctors selected healow Genie.
About America's Family Doctors
America's Family Doctors is a Patient-Centered Medical Home (PCMH) primary care practice dedicated to providing comprehensive, top-quality healthcare services to patients across multiple locations in Tennessee. The practice offers a wide range of primary care, urgent care, and specialty services, focusing on patient-centered care and exceptional medical expertise. For more information, visit afdclinics.com.
About eClinicalWorks
eClinicalWorks was founded in 1999 to help digitize paper charts for ambulatory practices. Today, eClinicalWorks innovates the nation with cloud-based Electronic Health Records and Practice Management solutions. In addition, we help ambulatory practices, specialists, health centers, urgent care facilities, and hospital systems manage their revenue cycle, patient relationships, and Population Health initiatives. More than 180,000 providers and 1 million medical professionals rely upon the power and scalability of the eCW Cloud for flexible clinical documentation, better front-office workflows, and more efficient billing driven by Robotic Process Automation. We combine innovation, leading-edge technology, and a commitment to patient safety to enable practices to grow and thrive amid the challenges of 21st-century healthcare. For more information, visit www.eclinicalworks.com, follow us on LinkedIn, Facebook and X/Twitter, or call (866) 888-6929.
About healow Genie
healow® Genie is a first-of-its-kind, EHR-agnostic, AI-powered contact center solution designed to enhance patient engagement by providing patients 24/7 access to vital health information via voice call, text, or chatbot. It offers a comprehensive suite of features, including patient self-service, intelligent assistant, automated after-hours service, and conversational smart campaigns. Genie improves patient satisfaction, reduces administrative burdens on staff, and lowers overall operational costs. For more information, visit genie.healow.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients who received 300 mg of dazucorilant compared to patients who received placebo Exploratory analysis at the one-year mark shows continued significant improvement in overall survival between patients who received 300 mg of dazucorilant and those who received placebo only Corcept seeking guidance from United States and European regulators on optimum path forward REDWOOD CITY, Calif., June 05, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomized, double-blind, placebo-controlled Phase 2 study in which 249 patients with ALS were randomized to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo, daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in a long-term extension study in which all patients received 300 mg of dazucorilant. The primary endpoint in DAZALS was the difference in ALSFRS-R between patients who received dazucorilant and those who received placebo. Overall survival was a secondary endpoint. Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no deaths had occurred in the 83 patients who received 300 mg of dazucorilant, while there were five deaths in the 82-patient placebo group (p-value of 0.02). An exploratory analysis conducted at the one-year mark shows the survival benefit has continued. Patients randomized to 300 mg of dazucorilant lived significantly longer than patients who received placebo and did not switch to 300 mg of dazucorilant in the extension study. The difference between groups was pronounced, with a hazard ratio of 0.16 (p-value: 0.0009). See Figure 1. A similar survival benefit was observed in patients who received 300 mg of dazucorilant for greater than 24 weeks, either in the treatment period or in the extension study, compared to patients who received either placebo or 150 mg of dazucorilant for 24 weeks and did not receive dazucorilant in the extension study (hazard ratio: 0.36; p-value 0.02). See Figure 2. The extension study is ongoing. Dazucorilant has demonstrated an acceptable safety profile, with 92 percent of adverse events being mild to moderate in severity. The frequency of severe and serious adverse events in patients who received dazucorilant was similar to those who received placebo. Mild to moderate, dose-related, transient abdominal pain was the most common adverse effect. "The improvement in overall survival, first noted in the DAZALS study at six months, continues to be seen at one-year. This finding deserves our full attention in service to patients with this tragic disease. Progress in the development of new ALS treatments is of critical importance," said Leonard H. van den Berg, M.D., Ph.D., Professor and Chair in the Department of Neurology, UMC Utrecht Brain Centre, Utrecht, The Netherlands, and Principal Investigator in the DAZALS study. "Medications that can extend life for patients with ALS are urgently needed. We are working with regulatory authorities to determine the optimal path for advancing dazucorilant," said Bill Guyer, PharmD, Corcept's Chief Development Officer. "We would like to thank the patients, their families and care partners, as well as the investigators, doctors and clinic staff involved in this study." About the DAZALS Study DAZALS is a randomized, double-blind, placebo-controlled Phases 2 trial in which 249 patients with ALS were randomized 1:1:1 to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in the long-term extension study in which all patients received 300 mg of dazucorilant. Baseline patient characteristics, including the ENCALS risk score, time from diagnosis, ALSFRS-R total score, and bulbar onset, were consistent across study arms. The DAZALS primary endpoint was the difference in change from baseline during the study's 24-week treatment period in ALSFRS-R score between patients who received dazucorilant and those who received placebo. Key secondary endpoints include overall survival and quality of life. DAZALS was conducted at sites in Europe, the United States and Canada. About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig's disease or motor neuron disease, is a fatal degenerative neurologic disorder that affects more than 55,000 people in the United States and Europe. ALS causes muscles to weaken and, as the disease progresses, severely impairs patients' ability to speak, eat, move and breathe. There is increasing evidence that patients with ALS, particularly those with rapid disease progression, exhibit elevated or abnormal cortisol levels. A patient's life expectancy after diagnosis is two to five years. About Dazucorilant Dazucorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but does not bind to the body's other hormone receptors. Corcept is studying it as a potential treatment for ALS and other neurologic disorders. Dazucorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. The U.S. Food and Drug Administration has granted dazucorilant Fast Track Designation and orphan drug status for the treatment of ALS in the United States. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations, which are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties are set forth in our SEC filings, which are available at our website and the SEC's website. In this press release, forward-looking statements include those concerning the development of dazucorilant as a treatment for patients with ALS, including the pace, conduct, timing and outcome of DAZALS and its associated long-term extension study, as well as oversight or requirements that may be imposed by the FDA or other regulatory authorities. We disclaim any intention or duty to update forward-looking statements made in this press release. View source version on Contacts Investor inquiries:ir@ Media inquiries:communications@
Yahoo
an hour ago
- Yahoo
Yumeiren International Group Shines at Malaysia's IBE
HANGZHOU, China, June 05, 2025--(BUSINESS WIRE)--The four-day 2025 Malaysia IBE (International Beauty Expo) concluded successfully in Kuala Lumpur. This year's event brought together over 400 international brands and attracted more than 16,000 professional buyers, forming a robust business network spanning 28 countries. As a leader in China's medical aesthetics going global, Yumeiren stood out at the expo with its integrated approach to life cosmetology, medical cosmetology, and greater health. The company invited Southeast Asian partners to join its service network—marking a strategic step in its global growth and advancing the international presence of China's medical cosmetology. From its founding in 1993 to its global debut in Kuala Lumpur, Yumeiren has spent 33 years shaping the sustained growth of a Chinese medical beauty brand. This is not merely business expansion—it is an industry evolution that has weathered economic cycles, embraced technological shifts, and bridged cultural divides. Under the leadership of President Yu Wenhong, Yumeiren built its foundation from the ground up, uniting lifestyle beauty and medical cosmetology into the Artistic Facial Shaping platform. With passion, vision, and professionalism, she guided the company into a new era of precision development—continuously enhancing service systems, integrating multidisciplinary health management, and expanding into the broader wellness space. Through strategic integration and innovation, Yumeiren launched its Forever Young Healthcare System, using science to slow aging and empowering individuals to take control of their health and longevity. Even before the expo began, numerous Malaysian organizations actively reached out to Yumeiren seeking collaboration. In response, President Yu Wenhong and her team arrived in Kuala Lumpur early to evaluate potential partners and begin training local doctors—ensuring seamless integration of Chinese aesthetic standards with Malaysian medical practices and establishing Yumeiren as part of the local ecosystem. During the expo, Yumeiren's booth drew large crowds. The team shared the company's growth story and brand strengths, deepening attendees' understanding and reinforcing confidence in the brand, while clearly communicating partnership expectations and value. With over 30 years of experience, Yumeiren has built a solid operational and brand framework that ensures reliability—earning lasting trust from clients and attracting an increasing number of committed partners. The success of this expo showcased Yumeiren's strengths and highlighted strong interest from global markets. Committed to delivering professional service, Yumeiren will continue bringing health, youth, and beauty to the world. View source version on Contacts Cathy Cai, ymrinternational@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Yumeiren International Group Shines at Malaysia's IBE
HANGZHOU, China--(BUSINESS WIRE)--The four-day 2025 Malaysia IBE (International Beauty Expo) concluded successfully in Kuala Lumpur. This year's event brought together over 400 international brands and attracted more than 16,000 professional buyers, forming a robust business network spanning 28 countries. As a leader in China's medical aesthetics going global, Yumeiren stood out at the expo with its integrated approach to life cosmetology, medical cosmetology, and greater health. The company invited Southeast Asian partners to join its service network—marking a strategic step in its global growth and advancing the international presence of China's medical cosmetology. From its founding in 1993 to its global debut in Kuala Lumpur, Yumeiren has spent 33 years shaping the sustained growth of a Chinese medical beauty brand. This is not merely business expansion—it is an industry evolution that has weathered economic cycles, embraced technological shifts, and bridged cultural divides. Under the leadership of President Yu Wenhong, Yumeiren built its foundation from the ground up, uniting lifestyle beauty and medical cosmetology into the Artistic Facial Shaping platform. With passion, vision, and professionalism, she guided the company into a new era of precision development—continuously enhancing service systems, integrating multidisciplinary health management, and expanding into the broader wellness space. Through strategic integration and innovation, Yumeiren launched its Forever Young Healthcare System, using science to slow aging and empowering individuals to take control of their health and longevity. Even before the expo began, numerous Malaysian organizations actively reached out to Yumeiren seeking collaboration. In response, President Yu Wenhong and her team arrived in Kuala Lumpur early to evaluate potential partners and begin training local doctors—ensuring seamless integration of Chinese aesthetic standards with Malaysian medical practices and establishing Yumeiren as part of the local ecosystem. During the expo, Yumeiren's booth drew large crowds. The team shared the company's growth story and brand strengths, deepening attendees' understanding and reinforcing confidence in the brand, while clearly communicating partnership expectations and value. With over 30 years of experience, Yumeiren has built a solid operational and brand framework that ensures reliability—earning lasting trust from clients and attracting an increasing number of committed partners. The success of this expo showcased Yumeiren's strengths and highlighted strong interest from global markets. Committed to delivering professional service, Yumeiren will continue bringing health, youth, and beauty to the world.
